Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | growth hormone secretagogue receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | rhodopsin-like orphan GPCR | growth hormone secretagogue receptor | 289 aa | 243 aa | 23.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical oxidoreductase | 0.0027 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0089 | 0.3033 | 0.5 |
Onchocerca volvulus | 0.0027 | 0 | 0.5 | |
Entamoeba histolytica | type A flavoprotein, putative | 0.0089 | 0.3033 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0234 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0234 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0234 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0089 | 0.3033 | 0.3033 |
Treponema pallidum | flavodoxin | 0.0089 | 0.3033 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0234 | 1 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0089 | 0.3033 | 0.3033 |
Trypanosoma cruzi | p450 reductase, putative | 0.0234 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0116 | 0.4316 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0089 | 0.3033 | 0.5 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0089 | 0.3033 | 0.3033 |
Echinococcus multilocularis | methionine synthase reductase | 0.0144 | 0.5684 | 0.5684 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0118 | 0.4402 | 0.4402 |
Chlamydia trachomatis | sulfite reductase | 0.0144 | 0.5684 | 1 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0089 | 0.3033 | 0.3033 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0234 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0234 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0234 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0144 | 0.5684 | 0.5684 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0234 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0234 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0089 | 0.3033 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0234 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0234 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0144 | 0.5684 | 0.5684 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0089 | 0.3033 | 0.3033 |
Leishmania major | cytochrome P450 reductase, putative | 0.0207 | 0.8717 | 0.8717 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0234 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0234 | 1 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0089 | 0.3033 | 0.3033 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0089 | 0.3033 | 0.3033 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0234 | 1 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0144 | 0.5684 | 0.5684 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0089 | 0.3033 | 0.3033 |
Plasmodium vivax | hypothetical protein, conserved | 0.0089 | 0.3033 | 0.3033 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0207 | 0.8717 | 0.8717 |
Giardia lamblia | Hypothetical protein | 0.0207 | 0.8717 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0144 | 0.5684 | 0.5684 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0234 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0116 | 0.4316 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0234 | 1 | 1 |
Mycobacterium tuberculosis | Possible electron transfer protein FdxB | 0.0027 | 0 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0207 | 0.8717 | 0.8159 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0234 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0027 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable monooxygenase | 0.0027 | 0 | 0.5 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0116 | 0.4316 | 0.4316 |
Leishmania major | p450 reductase, putative | 0.0234 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxygenase | 0.0027 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0234 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0234 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0234 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0089 | 0.3033 | 0.3033 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0207 | 0.8717 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0089 | 0.3033 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Cmax (ADMET) | = 1.5 uM | Cmax in CD1 mouse at 2 mg/kg, po by LC-MS/MS method | ChEMBL. | 24967667 |
IC50 (binding) | = 15 nM | Displacement of [125I]human ghrelin from human GHS-R1a expressed in HEK cell membranes after 60 mins by gamma counting method | ChEMBL. | 24967667 |
max activation (binding) | = 96 % | Inverse agonist activity at human GHS-R1a expressed in Tango U2OS-GHS-R1a cells by FLIPR based assay | ChEMBL. | 24967667 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.